Caption Management LLC lowered its position in shares of The Chemours Company (NYSE:CC - Free Report) by 93.9% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,694 shares of the specialty chemicals company's stock after selling 117,980 shares during the period. Caption Management LLC's holdings in Chemours were worth $104,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Quarry LP bought a new position in shares of Chemours during the first quarter valued at about $95,000. Baird Financial Group Inc. purchased a new position in Chemours during the 1st quarter valued at about $148,000. State of Wyoming raised its position in Chemours by 13.4% during the 1st quarter. State of Wyoming now owns 13,978 shares of the specialty chemicals company's stock valued at $189,000 after purchasing an additional 1,657 shares during the last quarter. Landscape Capital Management L.L.C. raised its position in Chemours by 34.4% during the 1st quarter. Landscape Capital Management L.L.C. now owns 47,075 shares of the specialty chemicals company's stock valued at $637,000 after purchasing an additional 12,043 shares during the last quarter. Finally, Comerica Bank lifted its stake in Chemours by 13.1% in the first quarter. Comerica Bank now owns 64,738 shares of the specialty chemicals company's stock worth $876,000 after acquiring an additional 7,498 shares during the period. Institutional investors own 76.26% of the company's stock.
Chemours Price Performance
Shares of Chemours stock traded up $0.56 during trading on Friday, reaching $15.65. 4,308,402 shares of the stock traded hands, compared to its average volume of 3,434,551. The Chemours Company has a 52-week low of $9.13 and a 52-week high of $22.38. The company has a debt-to-equity ratio of 17.16, a current ratio of 1.68 and a quick ratio of 0.83. The business has a fifty day simple moving average of $13.73 and a two-hundred day simple moving average of $12.72. The company has a market capitalization of $2.34 billion, a price-to-earnings ratio of -5.59 and a beta of 1.61.
Chemours (NYSE:CC - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.12. The company had revenue of $1.62 billion during the quarter, compared to analyst estimates of $1.57 billion. Chemours had a positive return on equity of 35.14% and a negative net margin of 7.19%.The firm's revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.38 earnings per share. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts expect that The Chemours Company will post 2.03 EPS for the current year.
Chemours Cuts Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Investors of record on Friday, August 15th will be paid a dividend of $0.0875 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.35 dividend on an annualized basis and a yield of 2.2%. Chemours's dividend payout ratio is presently -12.50%.
Insider Buying and Selling
In other Chemours news, CEO Denise Dignam acquired 4,068 shares of the stock in a transaction on Friday, August 8th. The stock was acquired at an average price of $12.06 per share, for a total transaction of $49,060.08. Following the completion of the transaction, the chief executive officer directly owned 191,546 shares of the company's stock, valued at $2,310,044.76. This trade represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.34% of the stock is owned by company insiders.
Analysts Set New Price Targets
A number of research analysts have recently commented on CC shares. Zacks Research upgraded Chemours from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Morgan Stanley cut their price target on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a report on Monday, May 12th. Wall Street Zen downgraded Chemours from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Mizuho lifted their target price on shares of Chemours from $13.00 to $16.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 15th. Finally, Royal Bank Of Canada upped their price target on shares of Chemours from $14.00 to $15.00 and gave the company an "outperform" rating in a research report on Thursday, July 3rd. Five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $17.38.
Get Our Latest Stock Report on CC
About Chemours
(
Free Report)
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
Recommended Stories

Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.